B型/C型肝炎治療の米国市場における戦略的分析

Abstract

This Frost & Sullivan research service entitled Strategic Analysis of U.S. Hepatitis B and C Markets provides strategic recommendations and SWOT analysis, patient and pricing forecasts, market share analysis, and analysis of existing and new products. In this research, Frost & Sullivan's expert analysts thoroughly examine the Total Market along with the U.S. Hepatitis B and U.S. Hepatitis C Markets.

This analysis is available through our Pharmaceutical & Biotechnology Growth Partnership Services program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils.

Table of Contents

1. Executive Summary

• 1. Executive Summary
  • 1. Executive Summary

2. Total Hepatitis Markets

• 1. Market Overview
  • 1. Introduction
  • 2. Market Segmentation
  • 3. Research Methodology
• 2. SWOT Analysis and Revenue Forecast
  • 1. SWOT Analysis
  • 2. Revenue Forecasts
• 3. Industry Challenges and Strategies
  • 1. Industry Challenges
  • 2. Strategic Recommendations
• 4. Frost and Sullivan Awards
  • 1. Entrepreneurial Company Award

3. U.S. Hepatitis B Market

• 1. Market Overview
  • 1. Introduction
  • 2. Market Engineering Measurements
• 2. Market Forecast and Trends
  • 1. Patient Forecast
  • 2. Pricing Forecast
  • 3. Revenue Forecast
  • 4. Market Trends
• 3. Competitive Analysis
  • 1. Competitive Structure
  • 2. Market Share Analysis

4. U.S. Hepatitis C Market

• 1. Market Overview
  • 1. Introduction
  • 2. Market Engineering Measurements
• 2. Market Forecast
  • 1. Patient Forecast
  • 2. Pricing Forecast
  • 3. Revenue Forecast
  • 4. Market Trends
• 3. Competitive Analysis
  • 1. Competitive Structure
  • 2. Market Share Analysis

5. Decision Support Databases

• 1. Disease Incidence
  • 1. HIV Prevalence
  • 2. AIDS Incidence
  • 3. Hepatitis B Incidence
• 2. Healthcare Expenditure
  • 1. Pharmaceutical R&D Expenditure
  • 2. Percentage Pharmaceutical R&D Expenditure
  • 3. Total Healthcare Expenditure